First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report
Molecular Therapy: Oncology
· Elsevier
Аннотация
Publication date: 17 December 2026 Source: Molecular Therapy Oncology, Volume 34, Issue 4 Author(s): Guangfei Li, Yuting Lai, Liang Wang, Hongjia Zhu, Min Chen, Jifang Wang, Taomin Huang, Liqing Kang, Nan Xu, Minghao Li, Xiaoyan Lou, Zhou Yu, Wei Wang, Minghao Fan, Jiali Wu, Haitao Wu, Lei Yu, Peijie He, Hongmeng Yu, Jian Chen
Читать у издателя →
Цитирование
First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all
First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all
“First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report.” Molecular Therapy: Oncology.
@article{article59021,
title = {First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926002420?dgcid=rss_sd_all}
}